Skip to main content
. 2024 Oct 17;13(20):6187. doi: 10.3390/jcm13206187

Table 2.

Characteristics of the included patients categorized based on proton pump inhibitor utilization.

Characteristic Entire Cohort PPI Users PPI Non-Users p-Value
n = 41,084 n = 12,812 n = 28,272
Age, median (IQR) 52 (42–73) 52 (42–73) 52 (42–73) 0.08
Gender (Female), n (%) 20,800 (50.6) 6603 (51.5) 14,197 (50.2) 0.013
Weight, mean (SD) 75.1 (17.3) 74.4 (18) 75.4 (16.9) <0.001
CCI, mean (SD) 2.3 (2.2) 2.2 (2.1) 2.3 (2.2) 0.003
NPM, mean (SD) 6.5 (5.6) 5.7 (5.2) 6.9 (5.8) <0.001
CrCl, mean (SD) 98.7 (42) 98.6 (45) 98.7 (41) <0.001
Reported Comorbidities
Dementia, n (%) 55 (0.1) 15 (0.1) 40 (0.1) 0.5
Depression, n (%) 1599 (4) 466 (4) 1133 (4) 0.07
Pain, n (%) 25,257 (62) 7794 (61) 17,463 (62) 0.07
Gastritis-related disease, n (%) 13,563 (33) 4061 (32) 9502 (34) <0.001
Constipation, n (%) 3842 (9) 1134 (9) 2708 (10) 0.02
Renal Disease, n (%) 600 (2) 190 (2) 410 (2) 0.8
Anemia, n (%) 10,025 (24) 3085 (24) 6940 (25) 0.3
Respiratory disorder, n (%) 3586 (9) 1134 (9) 2452 (9) 0.6
Arthritis-related disease, n (%) 29,012 (71) 9018 (70) 19,994 (71) 0.5
Osteoporosis, n (%) 7912 (19) 2430 (19) 5482 (19) 0.3
Co-prescribed Medications
Antacid, n (%) 2241 (6) 689 (5) 1552 (6) 0.6
Anticoagulants, n (%) 4646 (11) 1514 (12) 3132 (11) 0.03
Antiplatelets, n (%) 5036 (12) 1655 (13) 3381 (12) 0.006
CCB, n (%) 3997 (10) 1327 (10) 2670 (9) 0.004
Nitrate, n (%) 443 (1) 154 (1) 289 (1) 0.1
NSAID, n (%) 19,504 (48) 6135 (48) 13,369 (47) 0.3
TCA, n (%) 1375 (3) 436 (3) 939 (3) 0.7
SSRI, n (%) 335 (1) 108 (1) 227 (1) 0.7
Paracetamol, n (%) 24,163 (59) 7507 (59) 16,656 (59) 0.5

PPI: Proton pump inhibitor, IQR: Inter-quartile range, SD: Standard range, CCI: Charlson comorbidity index, NPM: Number of prescribed medications, CrCl: Creatinine clearance. CCB: Calcium channel blocker, NSAID: Non-steroidal anti-inflammatory drugs, TCA: Tricyclic anti-depressant, SSRI: Selective serotonin reuptake inhibitor.